Literature DB >> 24588618

Quantitation of physiological and biochemical barriers to siRNA liver delivery via lipid nanoparticle platform.

Yan Xu1, Mei Ou, Ed Keough, Jeff Roberts, Ken Koeplinger, Mike Lyman, Scott Fauty, Ed Carlini, Melissa Stern, Rena Zhang, Suzie Yeh, Elizabeth Mahan, Yi Wang, Don Slaughter, Marian Gindy, Conrad Raab, Charles Thompson, Jerome Hochman.   

Abstract

Effective delivery of small interfering RNA (siRNA) requires efficient cellular uptake and release into cytosol where it forms an active complex with RNAi induced silencing complex (RISC). Despite rapid developments in RNAi therapeutics, improvements in delivery efficiency of siRNA are needed to realize the full potential of this modality in broad therapeutic applications. We evaluated potential physiological and biochemical barrier(s) to the effective liver delivery of siRNA formulated in lipid nanoparticle (LNP) delivery vehicles. The comparative siRNA delivery performance of three LNPs was investigated in rats. They were assembled with either C14- or C18-anchored PEG-lipid(s), cationic lipid(s), and various helper lipid(s) and contained the same siRNA duplex. These LNPs demonstrated differentiated potency with ED50's ranging from 0.02 to 0.25 mg/kg. The two C14-PEG-LNPs had comparable siRNA exposure in plasma and liver, while the C18-PEG-LNP demonstrated a higher plasma siRNA exposure and a slower but sustained liver uptake. RISC bound siRNA within the liver, a more proximal measure of the pharmacologically active siRNA species, displayed loading kinetics that paralleled the target mRNA knockdown profile, with greater RISC loading associated with more potent LNPs. Liver perfusion and hepatocyte isolation experiments were performed following treatment of rats with LNPs containing VivoTag-fluorescently labeled siRNA. One hour after dosing a majority of the siRNA within the liver was associated with hepatocytes and was internalized (within small subcellular vesicles) with no significant cell surface association, indicating good liver tissue penetration, hepatocellular distribution, and internalization. Comparison of siRNA amounts in hepatocytes and subcellular fractions of the three LNPs suggests that endosomal escape is a significant barrier to siRNA delivery where cationic lipid seems to have a great impact. Quantitation of Ago-2 associated siRNA revealed that after endosomal escape further loss of siRNA occurs prior to RISC loading. This quantitative assessment of LNP-mediated siRNA delivery has highlighted potential barriers with respect to endosomal escape and incomplete RISC loading for delivery optimization efforts.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24588618     DOI: 10.1021/mp400584h

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  11 in total

Review 1.  Using macropinocytosis for intracellular delivery of therapeutic nucleic acids to tumour cells.

Authors:  Arpan S Desai; Morag R Hunter; Alexander N Kapustin
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-02-04       Impact factor: 6.237

2.  Antibody responses to crucial functional epitopes as a novel approach to assess immunogenicity of vaccine adjuvants.

Authors:  Sita Awasthi; Lauren M Hook; Gokul Swaminathan; Tina M Cairns; Benjamin Brooks; Jeffrey S Smith; Noah T Ditto; Marian E Gindy; Andrew J Bett; Amy S Espeseth; Gary H Cohen; Harvey M Friedman
Journal:  Vaccine       Date:  2019-05-29       Impact factor: 3.641

3.  Nucleic Acid-Loaded Lipid Nanoparticle Interactions with Model Endosomal Membranes.

Authors:  Alice Spadea; Mark Jackman; Lili Cui; Sara Pereira; M Jayne Lawrence; Richard A Campbell; Marianne Ashford
Journal:  ACS Appl Mater Interfaces       Date:  2022-06-27       Impact factor: 10.383

4.  Identification of microRNAs involved in gefitinib resistance of non-small-cell lung cancer through the insulin-like growth factor receptor 1 signaling pathway.

Authors:  Wei Ma; Yanhong Kang; Lanlan Ning; Jie Tan; Hanping Wang; Yi Ying
Journal:  Exp Ther Med       Date:  2017-07-28       Impact factor: 2.447

5.  Mathematical Modeling: A Tool for Optimization of Lipid Nanoparticle-Mediated Delivery of siRNA.

Authors:  Radu Mihaila; Dipali Ruhela; Edward Keough; Elena Cherkaev; Silvia Chang; Beverly Galinski; René Bartz; Duncan Brown; Bonnie Howell; James J Cunningham
Journal:  Mol Ther Nucleic Acids       Date:  2017-04-12

6.  Phosphorylation-specific status of RNAi triggers in pharmacokinetic and biodistribution analyses.

Authors:  Vladimir S Trubetskoy; Jacob B Griffin; Anthony L Nicholas; Eric M Nord; Zhao Xu; Ryan M Peterson; Christine I Wooddell; David B Rozema; Darren H Wakefield; David L Lewis; Steven B Kanner
Journal:  Nucleic Acids Res       Date:  2017-02-17       Impact factor: 16.971

7.  Improved Efficacy in a Fabry Disease Model Using a Systemic mRNA Liver Depot System as Compared to Enzyme Replacement Therapy.

Authors:  Frank DeRosa; Lianne Smith; Yinghua Shen; Yan Huang; Jing Pan; Hongsheng Xie; Barak Yahalom; Michael W Heartlein
Journal:  Mol Ther       Date:  2019-03-06       Impact factor: 11.454

Review 8.  miRNAs in Cancer (Review of Literature).

Authors:  Beata Smolarz; Adam Durczyński; Hanna Romanowicz; Krzysztof Szyłło; Piotr Hogendorf
Journal:  Int J Mol Sci       Date:  2022-03-03       Impact factor: 5.923

Review 9.  Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract.

Authors:  Yuan Zhang; Juhura G Almazi; Hui Xin Ong; Matt D Johansen; Scott Ledger; Daniela Traini; Philip M Hansbro; Anthony D Kelleher; Chantelle L Ahlenstiel
Journal:  Int J Mol Sci       Date:  2022-02-22       Impact factor: 5.923

10.  Identification of siRNA delivery enhancers by a chemical library screen.

Authors:  Jerome Gilleron; Prasath Paramasivam; Anja Zeigerer; William Querbes; Giovanni Marsico; Cordula Andree; Sarah Seifert; Pablo Amaya; Martin Stöter; Victor Koteliansky; Herbert Waldmann; Kevin Fitzgerald; Yannis Kalaidzidis; Akin Akinc; Martin A Maier; Muthiah Manoharan; Marc Bickle; Marino Zerial
Journal:  Nucleic Acids Res       Date:  2015-07-28       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.